Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells
-Engaging in Joint Research to Create New Cancer Diagnostic Value and Applying It to Drug Research-
Sysmex to Exhibit the RF-500 Flow Cytometer for the Research and Industrial Domains at the Molecular Biology Society of Japan and the Japanese Society for Immunology
Sysmex Signs Agreement with National Health Laboratory of Myanmar to Provide Scientific Support Activities Aimed at Enhancing the Quality of Clinical Testing
Sysmex Wins Awards in 2016 Kinki Local Commendations for Inventions
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2017 (PDF:875KB)
Announcement Regarding Differences between Actual and Forecast Figures for the Six Months Ended September 30, 2016, and Revision of Full-Year Financial Results Forecasts (PDF:90KB)
Announcement Regarding Dividends from Surplus (Interim) and Revised Forecast for the Year-End Dividend (PDF:81KB)
Sysmex Receives “Eruboshi” Certification as an Excellent Company Based on the Act on Promotion of Women’s Participation and Advancement in the Workplace
Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the First Time
Sysmex’s Automated Blood Coagulation Analyzer Certified Under the 5th Heritage Program of Legacy Analytical Instruments/Scientific Instruments
Sysmex Wins the 14th Annual Merit Award from the Minister of Economy, Trade and Industry for Collaborative Achievement Between Industry, Academia and Government
Donation to “International Clinical Cancer Research Center” (provisional name) of Kobe University
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2017 (PDF:857KB)
Sysmex Proposal for Laboratory Quality Control Support Project in the Republic of Namibia under JICA’s Collaboration Program with the Private Sector for Disseminating Japanese Technology
Sysmex, Healios and Sumitomo Dainippon Pharma Begin Joint R&D Related to Pre-Transplant Immune Reaction Testing Method for Retinal Pigment Epithelial Cells (RPE Cells) Derived from Allogeneic iPS Cells
Sysmex Pursuing Joint Development with GL-i to Provide New Diagnostic Reagents Employing Glycosylation Markers
Our Views and Policy regarding Investment Unit Reduction (PDF:75KB)
Sysmex Acquires Additional Shares in RIKEN GENESIS and Converts Company to a Subsidiary
-Reinforcing Our Structure Toward the Practical Realization of Genomic Medicine-
Announcement of Partial Revision of the Articles of Incorporation (PDF:74KB)
Sysmex Asia Pacific Establishes Branch in Myanmar
-Aiming to Help Raise the Level of Healthcare in Myanmar-
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2016 (PDF:652KB)
Sysmex Announces Changes from Financial Results Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2016 (PDF:142KB)
Sysmex Records Loss on Valuation of Investments in Capital of Subsidiaries and Associates and Conducts Lump-Sum Amortization of Goodwill in Relation to Sysmex Inostics (PDF:83KB)
Announcement of Executive Change (PDF:57KB)
Sysmex Provides Donation for Kumamoto Earthquake Relief
Sysmex and Siemens Extend Long-standing Global Partnership in Hemostasis Testing
New Liquid Biopsy RAS Testing for metastatic colorectal cancer patients now available for clinical practices
Sysmex Signs Agreement with Mongolia’s Ministry of Health and Sports to Support Activities to Create External Quality Controls and a Reference Laboratory
Sysmex to Be Special Sponsor of the Kobe Marathon 2016
-We are pleased to have sponsored this exciting event since its inception in 2011-
Sysmex Begins Joint Development of Imaging FCM Products with Merck
Sysmex and JVCKENWOOD to Commence Joint Development of Diagnostic Instruments for Measurement of Exosomes
Announcement of Organizational and Personnel Changes (PDF:41KB)
FY2015 Nakatani Award and Research Grant Recipients Announced (PDF:131KB)
Sysmex to Transition to a Company with an Audit and Supervisory Committee (PDF:31KB)
Sysmex and Eisai enter comprehensive agreement to create next-generation diagnostic reagents in the field of dementia
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2016 (PDF:445KB)
Sysmex to Voluntarily Adopt International Financial Reporting Standards (IFRS) (PDF:24KB)
Sysmex Launches a New Product in the Sediment Urinalysis Testing Field, the UD-10 Fully-Automated Imaging Unit for Formed Elements in Urine
Sysmex Selected as One of 2016 Global 100’s Most Sustainable Companies in the World
Medicaroid Corporation’s US Subsidiary Commences Operations in Silicon Valley
Sysmex Enters Business Alliance Agreement with EIKEN CHEMICAL CO., LTD., Involving the Urine Chemistry Testing Business in Overseas Markets
Sysmex Launches the UC-3500 Fully-Automated Urine Chemistry Analyzer, its First Product in the Field of Urine Qualitative Analysis in Overseas Markets